Cover Image
市場調查報告書

心肌病:開發平台分析

Cardiomyopathy - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 253651
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
心肌病:開發平台分析 Cardiomyopathy - Pipeline Review, H2 2015
出版日期: 2015年09月23日 內容資訊: 英文 119 Pages
簡介

心肌症是心肌異常引起的疾病。其症狀有運動或安靜時的呼吸困難、腳、腳踝浮腫、咳嗽、倦怠感、暈眩、站立時眼前發黑、失神等。致病因子為家族病史、肥胖、酒精成癮、糖尿病、癌症治療等。治療方法包含有利尿劑,乙型阻斷劑,血管收縮素轉化酵素(ACE)抑制劑等。

本報告提供心肌病的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

心肌病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Array BioPharma Inc.
  • Bioheart, Inc.
  • Gilead Sciences, Inc.
  • Heart Metabolics Limited
  • Hemostemix Ltd
  • Kasiak Research Private Limited
  • miRagen Therapeutics, Inc.
  • MyoKardia, Inc.
  • Neurimmune Holding AG
  • Nyken BV
  • Sanofi
  • Shire Plc
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Private Limited
  • Torrent Pharmaceuticals Limited
  • Vericel Corporation
  • Virocan Therapeutics Private Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ACP-01
  • AdipoCell
  • AmVidcm-008
  • ARRY-797
  • binimetinib
  • CAP-1002
  • Cyndacel-M
  • Drugs for Dilated Cardiomyopathy
  • Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders
  • eleclazine
  • Gene Therapy for Cardiomyopathy
  • Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis
  • ixmyelocel-T
  • JR-100
  • Mesenchymal Stem Cells
  • MGN-9103
  • Monoclonal Antibodies for Cardiovascular Diseases
  • MYK-461
  • NI-301
  • NYK-1112
  • perhexiline maleate
  • Recombinant Peptide to Agonize GLP-1 for Cardiomyopathy
  • Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury
  • Refacell-DCM
  • SHP-627
  • Small Molecule for Dilated Cardiomyopathy
  • Stempeucel
  • TRC-120038
  • YS-1402

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7090IDB

Summary

Global Markets Direct's, 'Cardiomyopathy - Pipeline Review, H2 2015', provides an overview of the Cardiomyopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cardiomyopathy Overview
  • Therapeutics Development
    • Pipeline Products for Cardiomyopathy - Overview
    • Pipeline Products for Cardiomyopathy - Comparative Analysis
  • Cardiomyopathy - Therapeutics under Development by Companies
  • Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes
  • Cardiomyopathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cardiomyopathy - Products under Development by Companies
  • Cardiomyopathy - Products under Investigation by Universities/Institutes
  • Cardiomyopathy - Companies Involved in Therapeutics Development
    • Array BioPharma Inc.
    • Bioheart, Inc.
    • Gilead Sciences, Inc.
    • Heart Metabolics Limited
    • Hemostemix Ltd
    • Kasiak Research Private Limited
    • miRagen Therapeutics, Inc.
    • MyoKardia, Inc.
    • Neurimmune Holding AG
    • Nyken BV
    • Sanofi
    • Shire Plc
    • Stemedica Cell Technologies, Inc.
    • Stempeutics Research Private Limited
    • Torrent Pharmaceuticals Limited
    • Vericel Corporation
    • Virocan Therapeutics Private Limited
  • Cardiomyopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmVidcm-008 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARRY-797 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAP-1002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eleclazine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixmyelocel-T - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JR-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mesenchymal Stem Cells - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-9103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MYK-461 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NI-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NYK-1112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • perhexiline maleate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptide to Agonize GLP-1 for Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Refacell-DCM - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-627 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stempeucel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRC-120038 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YS-1402 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cardiomyopathy - Recent Pipeline Updates
  • Cardiomyopathy - Dormant Projects
  • Cardiomyopathy - Dormant Projects
  • Cardiomyopathy - Discontinued Products
  • Cardiomyopathy - Product Development Milestones
    • Featured News & Press Releases
      • Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy
      • Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
      • Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
      • Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy
      • Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan
      • Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy
      • Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure
      • Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
      • Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
      • Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cardiomyopathy, H2 2015
  • Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2015
  • Cardiomyopathy - Pipeline by Bioheart, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Gilead Sciences, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Heart Metabolics Limited, H2 2015
  • Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2015
  • Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2015
  • Cardiomyopathy - Pipeline by miRagen Therapeutics, Inc., H2 2015
  • Cardiomyopathy - Pipeline by MyoKardia, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Neurimmune Holding AG, H2 2015
  • Cardiomyopathy - Pipeline by Nyken BV, H2 2015
  • Cardiomyopathy - Pipeline by Sanofi, H2 2015
  • Cardiomyopathy - Pipeline by Shire Plc, H2 2015
  • Cardiomyopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
  • Cardiomyopathy - Pipeline by Stempeutics Research Private Limited, H2 2015
  • Cardiomyopathy - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
  • Cardiomyopathy - Pipeline by Vericel Corporation, H2 2015
  • Cardiomyopathy - Pipeline by Virocan Therapeutics Private Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2015
  • Cardiomyopathy - Dormant Projects, H2 2015
  • Cardiomyopathy - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Cardiomyopathy, H2 2015
  • Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top